What is Elanco Animal Health?
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide.
ELAN · Verdict
Moderate reward · elevated risk
ELAN has limited near-term tailwinds — valuation and volatility weigh on the model output.
Based on 88% data coverage
ELAN · Verdict
P/E 21.8× · PEG 4.04
Weak vs peers
-5% net margin · -3% ROE
Net debt/EBITDA 5.1×
Model-based scoring. For information only — not financial advice.
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. The company offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio Family, Interceptor Plus, Drontal family, and Drontal Plus; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well as osteoarthritis for dogs and cats under the Galliprant trademark. The company is listed on the NYSE in USA, operating in the Healthcare sector, with a market capitalisation of 11.97B.
The scoring profile indicates limited reward potential at this time, with momentum and size offering the most support. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.
For informational purposes only. Not financial advice.
A short list of Drug Manufacturers - Specialty & Generic names that are close enough in size to make side-by-side comparison useful.
| Shares sold | Shares bought | |
|---|---|---|
| 0-3months | 0 | 0 |
| 3-6months | 0 | 0 |
| 6-9months | 0 | 443,450 shares $938k |
| 9-12months | 0 | 0 |